Global Director, Sourcing
Eli Lilly & Company
Mr. Sutton is the global director of sourcing for Lilly’s manufacturing and human resources organizations. He has over 25 years experience with Eli Lilly and Company, having held various roles in support of the manufacturing organization including IT, supply chain operations, finance and procurement. He is responsible for developing and implementing the global sourcing strategies for API and dry product manufacturing, facilities management and utilities, as well as health, wellness and benefit programs, recruiting services and learning and development services.
Mr. Sutton has been an active DCAT event participant since 2000 and joined DCAT's Supply Chain Management Committee in 2011. He was appointed chairperson of the Supply Management Committee for 2013-2014 and served on the Board of Directors from 2010-2013.
He holds a B.S. in Management Information Systems from Brigham Young University and an M.B.A. from Indiana State University.
Senior Vice President Business Development
Mr. Magrì previously served as vice president of corporate business development at Infa, Inc. He joined Infa in 2005 as marketing and sales director. Since then, Infa has grown by acquisition to include sites in Italy and Spain and the business has expanded with the addition of a new division focused on contract manufacturing.
Previously, Mr. Magrì served as marketing and sales director at Sicor, which he joined in 2001, and in Teva’s API division, after the acquisition of Sicor in 2003.
His strong track record in the industry also includes previous roles at Archimica/Pro.Bio.Sint. and Fordras.
Mr. Magrì earned his Master’s degree in Chemistry and Pharmaceutical Technology from the University of Milan, Italy.
Stephan Kutzer, Ph.D.
Chief Executive Officer
Stephan brings valuable leadership experience with over 18 years in the pharmaceutical & biotech industry managing large contract services enterprises. Prior to joining Alcami, Dr. Kutzer served as Chief Operating Officer of Lonza’s Pharma & Biotech division which is part of the global chemicals and biotechnology company Lonza Group. Since 2003, he has also served as Chief Operating Officer and/or President of several divisions, including Lonza Custom Manufacturing, Lonza Biopharmaceuticals and Lonza Performance Chemicals. Dr. Kutzer holds a Master’s Degree in Chemical and Process Engineering and a Ph.D. in Engineering Sciences (Chemical Engineering) from the Technical University of Munich, Germany.
Director of Business Development, Early Intermediates
Mr. Diver has been in the pharmaceutical industry for over 28 years, having served technical and commercial leadership roles for both innovator companies and CDMOs. Currently, he is the Director, Business Development in the Lonza Pharma Biotech Segment at Lonza. Mr. Diver has been an active member of DCAT for many years participating on various committees, being the chair of the DCAT Technology Committee and has most recently served on the Advisory Council since 2015. Mr. Diver holds a B.S. in Chemical Engineering from Lehigh University.
Senior Director, Business Development
Gyma Laboratories of America, Inc.
Anita Anderson has been in the generic pharma industry for 20 years, holding various positions in sales and business development. She is currently the Senior Director of Business Development at Gyma Laboratories a position she has held since July 2016.
Ms. Anderson has been actively involved in the DCAT organization, holding positions on various committees, including chairperson of the Science and Scholarship Committee and as a member of the DCAT Advisory Council for the last three years. She serves as chairperson for the Board of Education in her hometown and is a member of the local Rotary Club.
Elizabeth Iorns, Ph.D.
Chief Executive Officer
Dr. Elizabeth Iorns is the Founder, President & CEO of Science Exchange; Chairman of Science Exchange Board of Directors; Co-Director of the Reproducibility Initiative; Board Director of the Drug, Chemical & Associated Technologies Association (DCAT); Advisory Board Member of Meta-Research Innovation Center at Stanford (METRICS); and a Part-time Partner at Y Combinator. Elizabeth has a Ph.D. in Cancer Biology from the Institute of Cancer Research (UK) and, before launching Science Exchange, was an Assistant Professor at University of Miami’s Miller School of Medicine where she investigated breast cancer development and progression. Elizabeth has been featured in multiple media outlets and she regularly speaks at thought leadership events, such as the 2017 TechCrunch Disrupt, 2017 Society for Laboratory Automation and Screening annual meeting and the 2016 MassBio CRO/CMO Symposium. Elizabeth has received a range of honors and recognition, including one of Goldman Sachs' '100 Most Intriguing Entrepreneurs'; finalist for Scrip's Executive of the Year Award; Kevin Abosch 'Women in Tech' portrait series; Nature Magazine’s 'Ten People Who Mattered'; ELLE's Women in Tech; University of Auckland's '40 Under 40 Alumni'; Stevie Awards Female Entrepreneur of the Year; University of London Chairman's Prize for Best Graduating PhD Student; the Kauffman Foundation Emerging Entrepreneur Award; and one of WIRED’s '50 Women Who Are Changing The World'.
Vice-President, Johnson & Johnson Business Services Procurement
Johnson & Johnson
Kerri McCullough Wood
Senior Vice President and Head of Commercial
Teva API, Inc.
Kerri McCullough Wood is currently Senior Vice President and Head of Commercial, TAPI, (Teva Active Pharmaceutical Ingredients). Kerri’s responsibilities include global responsibility for all commercial aspects of TAPI’s business, primarily, sales, marketing and customer experience activities. In 2016, TAPI reported growth in revenue to $777M, across a customer base of more than 1,000 organizations across the globe. Until her recent promotion, Kerri was Vice President, Head of TAPI Global Sales. Prior to that, Kerri held roles of increasing and varied responsibility in sales and marketing at Teva for the last 17 years.
Kerri earned a Master’s Degree in Business Administration from Fairleigh Dickinson University and holds a Bachelor’s Degree in Science from Boston College. Previously, Kerri served as the Chair of the Education Committee for DCAT.
Chief Executive Officer
Oliver Technow is President of BioVectra Inc., a Contract Development and Manufacturing and Organization (CDMO), based in Charlottetown, Prince Edward Island, Canada. He has more than 25 years of global experience in the Life Sciences sector with focuses in General Management, strategic marketing, market research, business development, pipeline management and product launches.
In his current role, Mr. Technow directs the Executive Leadership-Team at BioVectra that manages the company’s operations, offering services across the spectrum of the active pharmaceutical ingredient (API) manufacturing and custom drug development sector. BioVectra, a Mallinckrodt Pharmaceuticals company, manufactures ingredients for global pharmaceutical and biotechnology clients offering therapeutics used in the treatment of cancer, kidney disease, cardio-vascular disease, multiple sclerosis and many other serious diseases.
Mr. Technow serves as a Director of the Board for BIOTECanada and the PEI BioAlliance, as a Steering Council Member of Innovative Medicines Canada (IMC). In 2016, Mr. Technow was elected as an Advisory Council member of DCAT (Drug, Chemical and Associated Technologies Association) and most recently was elected to serve his first term on the DCAT Board of Directors (beginning November 1, 2017).
Prior to joining BioVectra , Mr. Technow served as President and General Manager of Eisai Limited in Mississauga, Canada, where he managed all business aspects in that nation from 2013 to June 2015. His past experience with Eisai spans leadership roles in the USA as Vice President, Established Products Global Business Unit; Vice President and Head of Global Marketing; and Director, CNS Business Unit, based in Frankfurt, Germany.
Mr. Technow’s career also includes roles at Fresenius AG, Bad Homburg, Germany. Mr. Technow completed and earned his Diploma as Industry Master from the Frankfurt Chamber of Commerce and Industry in Frankfurt, Germany. He is fluent in German and English.
Chief Executive Officer
Mr. Boyer is the chief executive officer at SCA Pharmaceuticals. Formerly he was senior vice president and business unit head of the Drug Product Division at AMRI. He joined AMRI in 2014 upon the acquisition of OSO BioPharmaceuticals where he served as president and CEO and was also a member of the Board of Directors. For the past 18 years, his assignments have been focused in contract manufacturing for both pharmaceuticals and biopharmaceuticals, developing experience and expertise for both drug substance and drug product. He holds a B.S. in Chemistry/Physics and an M.S. in Biochemistry.
Mr. Boyer is very active in trade groups and educational institutions that support the pharmaceutical and biopharmaceutical industry. In addition to DCAT, he currently serves on the External Advisory Board for the Department of Chemistry and Biology for the University of New Mexico. He has also been a member of other professional organizations, including the American Association of Pharmaceutical Scientists (AAPS), International Society of Pharmaceutical Engineers (ISPE) and the Parenteral Drug Association (PDA).
Dr. Folker Ruchatz
Corporate Vice President Product Supply and Lifecycle Management Human Pharma
Boehringer Ingelheim GmbH
Dr. Ruchatz is the Vice President of Corporate Product Supply and Lifecycle Management Human Pharma at Boehringer Ingelheim GmbH. He is responsible for the product supply and the portfolio/lifecycle management of Boehringer Ingelheim’s Corporate Division Human Pharma Supply and Global Quality. Previously he was responsible for the company’s external network of suppliers and all operations for consumer health care products. Joining the company in 2013, he first served as senior vice president of the contract manufacturing business biopharmaceuticals where he led new business strategies resulting in strong and profitable growth for the division. His prior work experience was at BASF Corporation. During that time, he was vice president of global business development customer synthesis and vice president of pharma solutions and dietary supplements.
Dr. Ruchatz has served as a member of DCAT’s Executive Committee since 2011. He was also a board member of the European Fine Chemical Group and Chairman of its Global Steering Committee of EXCiPACT.
Margaret M. Timony
Ms. Timony currently serves as the executive director of the Drug, Chemical & Associated Technologies Association (DCAT). Ms. Timony joined DCAT in December of 1998 after the organization moved its headquarters from New York to New Jersey. During her tenure, she has been responsible for overseeing the strategic direction and operations for the global business development association with 100+ active volunteers and a staff of 15.
Prior to this, Ms. Timony was the executive director of the American Physical Therapy Association of New Jersey (APTAnj) where she was responsible for the management and operations of the 2,500 member professional society which included legislative and regulatory advocacy. During her tenure at APTAnj, she also served concurrently as the executive director of the Acute Care practice section and the Research section for the national APTA organization.
A graduate of Widener University, she is active in association management professional societies and served as a board member and past president of the Middle Atlantic Society of Association Executives. She is also a member of the American Society of Association Executives and has led several small-staffed association group forums and committees.
The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.